Triosephosphate Isomerase from Mycobacterium tuberculosis as Potential Target to Develop a New Anti-TB Drug

Abstract

Tuberculosis (TB) is possibly the most prevalent infectious disease in the world, reports from the World Health Organization (WHO) indicate that TB is one of the top 10 causes of death and an estimated 10 million people worldwide, in addition, there are increasing the TB resistant to conventional antibiotics, multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB). Lastly, TB has become more important and requires more attention since it has been proposed as a risk factor for the severity of COVID-19. Therefore, the need to develop new anti-TB drugs. In this study, we propose to use the glycolytic enzyme triosephosphate isomerase from Mycobacterium tuberculosis (MtTIM) as a therapeutic target against TB. The triosephosphate isomerase (TIM) is a target used in different proposals to develop new drugs against different organisms. The MtTIM is an extremely attractive drug target due to the characteristics of its amino acids sequence. In addition, it has been determined that this enzyme (MtTIM) is necessary for the viability of in vitro and in vivo cultures of Mycobacterium tuberculosis. In this way, using the MtTIM as a therapeutic target, we propose potential compounds against MtTIM by molecular docking.